Navigating regulatory hurdles in the U.S. and Europe, plus fierce competition from rival Apellis, Astellas’ geographic ...

The continued evolution of treatment protocols and imaging modalities for the management of retinal diseases offer ... for the management of geographic atrophy secondary to age-related macular ...

“Although fundus autofluorescence is the gold standard ... Certain imaging biomarkers and demographic factors are associated with geographic atrophy growth rate and may guide the selection ...

Certain imaging biomarkers and demographic factors are associated with geographic atrophy growth rate and ... paired images to compare ultrawide field fundus autofluorescence (FAF) imaging with ...

Ministry of Health, Labour and Welfare to evaluate ACP as potential first and only treatment for patients with geographic atrophy (GA) secondary ...

Dublin, Jan. 07, 2025 (GLOBE NEWSWIRE) -- The "Geographic Atrophy Market Report 2024-2034" report has been added to ResearchAndMarkets.com's offering. This report will prove invaluable to leading ...

Geographic atrophy is a complex disease ... And just like we can’t replace brain cells if they’re lost, retinal cells don’t grow back when they die. But there’s some evidence that we ...

Astellas Pharma has submitted a new drug application (NDA) to Japan's Ministry of Health, Labour and Welfare seeking ...

In this Healio Video Perspective from Retina 2025, Roger A. Goldberg, MD, MBA, discusses the role of multimodal imaging in geographic atrophy in the era of complement inhibitors.Imaging confirms the ...

(Nasdaq: APLS) announced today that the Therapeutic Goods Administration (TGA) has approved SYFOVRE ® (pegcetacoplan) for the every-other-month treatment of adult patients with geographic atrophy ...

SBL03 was formulated as an ophthalmic gel for non-invasive topical delivery. Its unique ability to infiltrate eye tissues effectively and protect ret ...